Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corcept’s Second Corlux Phase III Trial Enrolled For Psychotic Major Depression

This article was originally published in The Pink Sheet Daily

Executive Summary

Company expects data from three Phase III trials of mifepristone for PMD by year-end.

You may also be interested in...

Mifeprex Post-Marketing Restriction Compliance To Be Questioned By Rep. Souder

Danco Labs declined to testify at a hearing on deaths associated with the use of the abortifacient mifepristone.

Lilly Funding Study Of Corcept's Corlux For Mitigation Of Zyprexa Weight Gain

Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.

Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression

The first of two trials testing rapid and sustained relief of psychotic features, designed under special protocol assessment with FDA, will begin "immediately," Corcept says. Corlux is expected to share the same safety restrictions as Mifeprex (RU-486).

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts